Dexosome cancer immunotherapy - Institute Gustave-Roussy/Therapeutics Solutions International

Drug Profile

Dexosome cancer immunotherapy - Institute Gustave-Roussy/Therapeutics Solutions International

Alternative Names: Autologous dendritic cell-derived exosomes; DEX

Latest Information Update: 19 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Institute Gustave-Roussy
  • Developer Duke University Medical Center
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cervical cancer; Colorectal cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 25 Jan 2016 Dexosome cancer immunotherapy product licensed to Therapeutic Solutions International
  • 25 Jan 2016 Therapeutic Solutions International in-licenses patent for dexosome cancer immunotherapy
  • 31 Jan 2007 Discontinued - Phase-I/II for Lung cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top